Is midostaurin available in China in 2024?

Midostaurin, whose English name isMidostaurin, is a small molecule inhibitor targeting multiple tyrosine kinase receptors and has attracted much attention from the global medical community. Its unique pharmacological effect lies in its ability to inhibit the activity of protein kinase Cα (PKCα), VEGFR2, KIT, PDGFR, and WT and/or mutant FLT3 tyrosine kinase, which brings new possibilities for anti-cancer treatment. However, although it has been widely used clinically abroad and has shown significant therapeutic effects, as of 2024, midostaurin has not yet been approved for sale in the domestic market.

For patients who are in urgent need of midostaurin, they may consider purchasing the drug overseas. In overseas markets, there are many versions of midostaurin available, including original drugs and generic drugs. Specifically, the European version of the original drug produced by Novartis is expensive, with a box (specification: 25mg*112 tablets) priced at more than 120,000 yuan. In comparison, the price of the Indian version of the original drug is more affordable, with a box (specification: 25mg*28 pills) priced at just over 3,000. What needs to be understood is that the ingredients and effects of the original medicine are exactly the same, and the difference in price is mainly due to differences in medical policies in different countries. In addition, the generic version of midostaurin produced by BDR Pharmaceuticals in India is more accessible to the people than the original drug. Each box has a specification of 25mg*28 pills and is priced at more than 2,000 yuan.

However, as a prescription drug, midostaurin must be used under the guidance of a doctor to ensure the effectiveness and safety of the drug. Before taking any medication, be sure to consult with your primary care physician to ensure that this medication is appropriate for your specific condition. Midostaurin is currently approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with FLT3 gene mutations. In addition, it can be used to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with hematological neoplasms (SM-AHN), and mast cell leukemia (MCL) in adults.

In general, although midostaurin has shown significant therapeutic effects abroad, as of2024, the drug has not been approved in the domestic market. For patients who need this drug, it can be purchased through regular overseas channels, but it must be used under the guidance of a doctor to ensure safety and effectiveness.